<DOC>
	<DOCNO>NCT01030861</DOCNO>
	<brief_summary>The study determine whether anti-CD3 monoclonal antibody , teplizumab , help prevent delay onset type 1 diabetes ( T1D ) relatives determined high risk develop disease . Teplizumab study new onset type 1 diabetes test efficacy safety previous study ; study currently progress . The result previous study indicate teplizumab reduces loss insulin production first year diagnosis individual type 1 diabetes . The purpose study determine teplizumab interdict immune process cause destruction insulin secrete beta cell pancreas `` pre-diabetic '' state thereby prevent delay onset type 1 diabetes .</brief_summary>
	<brief_title>Teplizumab Prevention Type 1 Diabetes In Relatives `` At-Risk ''</brief_title>
	<detailed_description>The study plan enroll approximately 71 subject age 8-45 year , 2-3 year . The study project last 4-6 year , depend upon rate enrollment number subject develop diabetes . The main study objective determine whether intervention teplizumab prevent delay development type 1 diabetes high risk autoantibody positive non-diabetic relative individual T1D . Secondary outcome include analyse C-peptide measure Oral Glucose Tolerance Testing ( OGTT ) , safety , tolerability , mechanistic outcome assess study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<criteria>Between age 845 year Have relative type 1 diabetes If first degree relative must 845 year old ( brother , sister , parent , offspring ) If second degree relative must 820 year old ( niece , nephew , aunt , uncle , grandchild , cousin ) Abnormal glucose tolerance OGTT confirm 7 week baseline visit [ fast blood glucose great 110mg/dL less 126 mg/dL OR 2 hour glucose great equal 140 mg/dL less 200 mg/dL OR 30 , 60 , 90 minute value OGTT great equal 200 mg/dL ] Presence least two confirmed diabetes autoantibody type 1 diabetes previously diagnose detect screen [ fast glucose great equal 126 mg/dL 2 hour glucose great equal 200 mg/dL ] abnormality blood count , liver enzymes , INR , positive PPD test vaccination live virus within 6 week randomization evidence acute infection base laboratory test clinical evidence serological evidence past current past HIV , hepatitis B , hepatitis C infection Be currently pregnant lactate Prior treatment study drug Prior treatment monoclonal antibody past one year</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>type 1 diabetes</keyword>
	<keyword>pre-diabetic</keyword>
	<keyword>autoantibody positive</keyword>
	<keyword>risk type 1 diabetes</keyword>
	<keyword>glucose intolerance</keyword>
	<keyword>relative people type 1 diabetes</keyword>
</DOC>